JP3336010B2 - 骨形成性蛋白の送達のための血餅−ポリマー・マトリックスの処方 - Google Patents
骨形成性蛋白の送達のための血餅−ポリマー・マトリックスの処方Info
- Publication number
- JP3336010B2 JP3336010B2 JP50721193A JP50721193A JP3336010B2 JP 3336010 B2 JP3336010 B2 JP 3336010B2 JP 50721193 A JP50721193 A JP 50721193A JP 50721193 A JP50721193 A JP 50721193A JP 3336010 B2 JP3336010 B2 JP 3336010B2
- Authority
- JP
- Japan
- Prior art keywords
- polymer matrix
- bone
- osteogenic
- poly
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 58
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 58
- 230000002188 osteogenic effect Effects 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 229920000642 polymer Polymers 0.000 title claims abstract description 24
- 239000011159 matrix material Substances 0.000 title claims abstract description 22
- 238000009472 formulation Methods 0.000 title description 13
- 230000010874 maintenance of protein location Effects 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 51
- 210000000988 bone and bone Anatomy 0.000 claims description 17
- 230000011164 ossification Effects 0.000 claims description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 10
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 5
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 4
- 230000022159 cartilage development Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 3
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 238000000164 protein isolation Methods 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 description 21
- 230000007547 defect Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 8
- 229960002684 aminocaproic acid Drugs 0.000 description 8
- 238000006065 biodegradation reaction Methods 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002138 osteoinductive effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 241001447056 Uristes Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002639 bone cement Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OORRCVPWRPVJEK-UHFFFAOYSA-N 2-oxidanylethanoic acid Chemical compound OCC(O)=O.OCC(O)=O OORRCVPWRPVJEK-UHFFFAOYSA-N 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003044 Closed Fractures Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006222 acrylic ester polymer Polymers 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 210000001909 alveolar process Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229920000984 poly(propylene-co-fumarate) Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/776,514 US5171579A (en) | 1991-10-11 | 1991-10-11 | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
US776,514 | 1991-10-11 | ||
PCT/US1992/008628 WO1993006872A1 (en) | 1991-10-11 | 1992-10-09 | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07500038A JPH07500038A (ja) | 1995-01-05 |
JP3336010B2 true JP3336010B2 (ja) | 2002-10-21 |
Family
ID=25107596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50721193A Expired - Fee Related JP3336010B2 (ja) | 1991-10-11 | 1992-10-09 | 骨形成性蛋白の送達のための血餅−ポリマー・マトリックスの処方 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5171579A (da) |
EP (1) | EP0608313B1 (da) |
JP (1) | JP3336010B2 (da) |
KR (1) | KR0181984B1 (da) |
AT (1) | ATE189611T1 (da) |
AU (1) | AU669133B2 (da) |
DE (1) | DE69230670T2 (da) |
DK (1) | DK0608313T3 (da) |
ES (1) | ES2145013T3 (da) |
GR (1) | GR3033204T3 (da) |
WO (1) | WO1993006872A1 (da) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US7208179B1 (en) | 1990-11-27 | 2007-04-24 | The American National Red Cross | Methods for treating disease and forming a supplemented fibrin matrix |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5739107A (en) * | 1991-03-11 | 1998-04-14 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
CA2161808C (en) * | 1993-05-12 | 2008-08-05 | Anthony J. Celeste | Bmp-11 compositions |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
AU689184B2 (en) | 1993-12-07 | 1998-03-26 | Genetics Institute, Llc | BMP-12, BMP-13 and tendon-inducing compositions thereof |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5962427A (en) * | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US6074840A (en) * | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
US5763416A (en) * | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
WO1995024210A1 (en) * | 1994-03-08 | 1995-09-14 | Genetics Institute, Inc. | Methods and compositions for treatment of periodontal disease and repair of periodontal lesions |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
DE69528128T2 (de) | 1994-06-10 | 2003-03-13 | United States Surgical Corp | Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung |
US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
PT955313E (pt) * | 1995-04-19 | 2006-07-31 | Bioph Biotech Entw Pharm Gmbh | Nova proteina e processo para a sua producao |
EP1364656B1 (en) * | 1995-06-05 | 2013-11-20 | Genetics Institute, LLC | Use of bone morphogenetic proteins for healing and repair of connective tissue attachment |
US6352972B1 (en) * | 1995-06-06 | 2002-03-05 | Marcel E. Nimni | Bone morphogenetic proteins and their use in bone growth |
US5674292A (en) | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
DE19548476A1 (de) * | 1995-12-22 | 1997-06-26 | Bioph Biotech Entw Pharm Gmbh | Zielgerichtete Verbindungen mit knorpel- und/oder knocheninduzierender Aktivität |
US5756652A (en) * | 1996-02-29 | 1998-05-26 | Depuy Orthopaedics, Inc. | Poly (ester-anhydrides) and intermediates therefor |
US5733868A (en) * | 1996-04-16 | 1998-03-31 | Depuy Orthopaedics, Inc. | Poly(amino acid) adhesive tissue grafts |
US5668288A (en) * | 1996-04-16 | 1997-09-16 | Depuy Orthopaedics, Inc. | Polyester ionomers for implant fabrication |
US6299905B1 (en) | 1996-04-16 | 2001-10-09 | Depuy Orthopaedics, Inc. | Bioerodable polymeric adhesives for tissue repair |
WO1998000161A1 (en) * | 1996-05-24 | 1998-01-08 | Buford Biomedical, Inc. | Fibrin-based systems for the controlled release of medicinals |
US6492508B1 (en) | 1996-06-03 | 2002-12-10 | United States Surgical Corp. A Division Of Tyco Healthcare Group | Nucleic acids encoding extracellular matrix proteins |
US6927287B1 (en) * | 1996-06-03 | 2005-08-09 | United States Surgical Corporation | Nucleic acid encoding extracellular matrix protein or fragment thereof |
US20040132653A1 (en) * | 1997-01-30 | 2004-07-08 | Biopharm Gmbh | Lyophilized composition of bone morphogenetic factor human MP52 |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
CA2297489A1 (en) | 1997-07-30 | 1999-02-11 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US6762336B1 (en) | 1998-01-19 | 2004-07-13 | The American National Red Cross | Hemostatic sandwich bandage |
US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
EP1212107B1 (en) * | 1999-08-31 | 2005-06-08 | Virginia Commonwealth University Intellectual Property Foundation | Engineered muscle |
AU774427B2 (en) | 1999-10-15 | 2004-06-24 | Fidia Advanced Biopolymers S.R.L. | Formulations of hyaluronic acid for delivery of osteogenic proteins |
DE10043151A1 (de) * | 2000-08-31 | 2002-03-28 | Peter Steinruecke | Knochenzement mit antimikrobieller Wirksamkeit |
US6648911B1 (en) | 2000-11-20 | 2003-11-18 | Avantec Vascular Corporation | Method and device for the treatment of vulnerable tissue site |
US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
ATE393573T1 (de) | 2001-06-01 | 2008-05-15 | Wyeth Corp | Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren |
TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
JP4614661B2 (ja) * | 2002-02-08 | 2011-01-19 | ワイス | 生体活性因子を含有する処方物およびそれを使用する方法 |
ES2434257T3 (es) * | 2002-06-06 | 2013-12-16 | The Brigham And Women's Hospital, Inc. | Coágulos de células hematopoyéticas no poliméricos para suministro de agentes activos |
JP4777650B2 (ja) | 2002-09-10 | 2011-09-21 | アメリカン ナショナル レッド クロス | 止血用包帯 |
DE10340277B4 (de) * | 2003-08-29 | 2006-11-23 | Bio-Gate Bioinnovative Materials Gmbh | Körperpflegemittel mit Silber-Agglomeraten |
RU2363478C2 (ru) | 2003-09-12 | 2009-08-10 | Вайет | Инъецируемые стержни из фосфата кальция для доставки остеогенных белков |
WO2005032344A2 (en) * | 2003-10-02 | 2005-04-14 | The Regents Of The University Of Michigan | Human prostate cancer cell factor(s) that induce stem cell commitment and osteogenesis |
JP4694163B2 (ja) * | 2004-07-26 | 2011-06-08 | 株式会社ジーシー | 生体吸収性顆粒状多孔質骨補填材の製造方法 |
EP1838335A1 (en) * | 2005-01-19 | 2007-10-03 | Bonoss Medical AB | Growth factor composition |
AU2007254824A1 (en) | 2006-06-02 | 2007-12-13 | Wyeth | Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods |
US7754689B2 (en) * | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
CA2657819C (en) * | 2006-07-21 | 2014-05-20 | Genera Doo | Whole blood-derived coagulum device for treating bone defects |
US20080033332A1 (en) * | 2006-08-04 | 2008-02-07 | Macphee Martin | Solid dressing for treating wounded tissue |
US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
WO2009020612A1 (en) * | 2007-08-06 | 2009-02-12 | Stb Lifesaving Technologies, Inc. | Methods and dressing for sealing internal injuries |
CN103313733A (zh) | 2010-11-15 | 2013-09-18 | 捷迈整形外科生物材料有限公司 | 骨空隙填充剂 |
US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
CN107753138A (zh) * | 2017-11-09 | 2018-03-06 | 中山大学附属口腔医院 | 一种评估微量元素成骨作用的方法及其动物模型的构建方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186448A (en) * | 1976-04-16 | 1980-02-05 | Brekke John H | Device and method for treating and healing a newly created bone void |
US4526909A (en) * | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
US4563489A (en) * | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
US4609551A (en) * | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
US4639366A (en) * | 1984-06-06 | 1987-01-27 | Merck & Co., Inc. | Polymers containing pendant acid functionalities and labile backbone bonds |
US4620327A (en) * | 1984-07-05 | 1986-11-04 | Caplan Arnold I | Process of adapting soluble bone protein for use in stimulating osteoinduction |
EP0383363A3 (en) * | 1984-11-29 | 1990-10-03 | Regents Of The University Of Minnesota | Use of wound healing agents |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US4902296A (en) * | 1986-10-29 | 1990-02-20 | The University Of Virginia Alumni Patents Foundation | Use of demineralized bone matrix in the repair of segmental defects |
US4743259A (en) * | 1986-10-29 | 1988-05-10 | The University Of Virginia Alumni Patents Foundation | Use of demineralized bone matrix in the repair of segmental defects |
WO1989004646A1 (en) * | 1987-11-13 | 1989-06-01 | Jefferies Steven R | Bone repair material and delayed drug delivery |
GB2215209B (en) * | 1988-03-14 | 1992-08-26 | Osmed Inc | Method and apparatus for biodegradable, osteogenic, bone graft substitute device |
US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
DE68918155T2 (de) * | 1988-05-02 | 1995-03-02 | Project Hear | Chirurgisches Klebstoffmaterial. |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5284756A (en) * | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
CA2056384C (en) * | 1989-06-05 | 1998-06-23 | Tobin N. Gerhart | Bioerodible polymers for drug delivery in bone |
ES2118723T3 (es) * | 1989-10-17 | 1998-10-01 | Stryker Corp | Dispositivos osteogenicos. |
US5645591A (en) * | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
MX9203083A (es) * | 1991-06-21 | 1994-08-31 | Genetics Inst | Formulaciones farmaceuticas de proteinas osteogenicas. |
-
1991
- 1991-10-11 US US07/776,514 patent/US5171579A/en not_active Expired - Lifetime
-
1992
- 1992-10-09 AT AT92921634T patent/ATE189611T1/de not_active IP Right Cessation
- 1992-10-09 ES ES92921634T patent/ES2145013T3/es not_active Expired - Lifetime
- 1992-10-09 JP JP50721193A patent/JP3336010B2/ja not_active Expired - Fee Related
- 1992-10-09 DE DE69230670T patent/DE69230670T2/de not_active Expired - Fee Related
- 1992-10-09 KR KR1019940701180A patent/KR0181984B1/ko not_active IP Right Cessation
- 1992-10-09 DK DK92921634T patent/DK0608313T3/da active
- 1992-10-09 AU AU27885/92A patent/AU669133B2/en not_active Ceased
- 1992-10-09 EP EP92921634A patent/EP0608313B1/en not_active Expired - Lifetime
- 1992-10-09 WO PCT/US1992/008628 patent/WO1993006872A1/en active IP Right Grant
-
2000
- 2000-04-12 GR GR20000400898T patent/GR3033204T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5171579A (en) | 1992-12-15 |
JPH07500038A (ja) | 1995-01-05 |
EP0608313A1 (en) | 1994-08-03 |
WO1993006872A1 (en) | 1993-04-15 |
DK0608313T3 (da) | 2000-05-15 |
KR0181984B1 (ko) | 1999-04-01 |
AU669133B2 (en) | 1996-05-30 |
GR3033204T3 (en) | 2000-08-31 |
DE69230670T2 (de) | 2000-09-21 |
ES2145013T3 (es) | 2000-07-01 |
ATE189611T1 (de) | 2000-02-15 |
AU2788592A (en) | 1993-05-03 |
DE69230670D1 (de) | 2000-03-16 |
EP0608313B1 (en) | 2000-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3336010B2 (ja) | 骨形成性蛋白の送達のための血餅−ポリマー・マトリックスの処方 | |
JP3351525B2 (ja) | 骨形成性蛋白医薬処方物 | |
AU695374B2 (en) | Formulations for delivery of osteogenic proteins | |
AU774427B2 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
EP1220693B1 (en) | Formulations for delivery of osteogenic proteins | |
JPH05507930A (ja) | 骨誘導医薬製剤 | |
US10960109B2 (en) | Autologous bone graft substitute | |
US11596712B2 (en) | Autologous bone graft substitute composition | |
EP1454640A2 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
EP1475109A1 (en) | Formulations for delivery of osteogenic proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |